Kim B. Luley

Luebeck, SH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Author Correction: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial.

Author Correction: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial.

Journal: Nature communications

Published: April 17, 2026

Personalized Combined Nutrition & Exercise Intervention in Newly Diagnosed Cancer Patients - a Trial Protocol.

Personalized Combined Nutrition & Exercise Intervention in Newly Diagnosed Cancer Patients - a Trial Protocol.

Journal: Future science OA

Published: October 09, 2025

First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial.

First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial.

Journal: Nature communications

Published: July 01, 2025

Which Immunotherapies are Standard Today? And What Side Effects Should be Expected?

Which Immunotherapies are Standard Today? And What Side Effects Should be Expected?

Journal: Zentralblatt fur Chirurgie

Published: April 08, 2025

Individually compounded multi-chamber vs. standardized parenteral nutrition bags in solid tumors-A randomized clinical trial (IKF-010).

Individually compounded multi-chamber vs. standardized parenteral nutrition bags in solid tumors-A randomized clinical trial (IKF-010).

Journal: Clinical nutrition ESPEN

Published: April 03, 2025

Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.

Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.

Journal: International journal of cancer

Published: September 28, 2023

Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.

Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 20, 2022

Differential Effects of Somatostatin, Octreotide, and Lanreotide on Neuroendocrine Differentiation and Proliferation in Established and Primary NET Cell Lines: Possible Crosstalk with TGF-β Signaling.

Differential Effects of Somatostatin, Octreotide, and Lanreotide on Neuroendocrine Differentiation and Proliferation in Established and Primary NET Cell Lines: Possible Crosstalk with TGF-β Signaling.

Journal: International journal of molecular sciences

Published: October 26, 2022

Tailored Systemic Therapy for Colorectal Cancer Liver Metastases.

Tailored Systemic Therapy for Colorectal Cancer Liver Metastases.

Journal: International journal of molecular sciences

Published: October 01, 2021

Resection of Non-Functional Pancreatic Neuroendocrine Neoplasms-A Single-Center Retrospective Outcome Analysis.

Resection of Non-Functional Pancreatic Neuroendocrine Neoplasms-A Single-Center Retrospective Outcome Analysis.

Journal: Current oncology (Toronto, Ont.)

Published: August 02, 2021

Gastroenteropancreatic neuroendocrine neoplasms-Heterogeneity, management and perspectives of treatment and research

Gastroenteropancreatic neuroendocrine neoplasms-Heterogeneity, management and perspectives of treatment and research

Journal: Der Internist

Published: July 18, 2020

A Comprehensive Molecular Characterization of the Pancreatic Neuroendocrine Tumor Cell Lines BON-1 and QGP-1.

A Comprehensive Molecular Characterization of the Pancreatic Neuroendocrine Tumor Cell Lines BON-1 and QGP-1.

Journal: Cancers

Published: February 11, 2020

Showing 1-12 of 22

Last Updated: 09/26/2026